Literature DB >> 1710580

Rapid purification and characterisation of HIV-1 reverse transcriptase and RNaseH engineered to incorporate a C-terminal tripeptide alpha-tubulin epitope.

D K Stammers1, M Tisdale, S Court, V Parmar, C Bradley, C K Ross.   

Abstract

The C-termini of p66 and p51 forms of HIV-1 reverse transcriptase have been engineered to contain a Glu-Glu-Phe sequence recognized by a monoclonal antibody to alpha-tubulin, YL1/2. Mutated RTs were purified in a single step using peptide elution from columns of immobilized YL1/2. The known sequence requirements of the YL1/2 epitope are consistent with protein eluting from the column with an intact C-terminus. Kinetic parameters of these mutated RTs are essentially unchanged from wild-type enzyme. The p15 RNaseH domain has been purified using this method and shown to have low enzyme activity compared to the parental p66 subunit.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710580     DOI: 10.1016/0014-5793(91)80613-8

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  16 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Characterization of HIV-1 reverse transcriptase with antibodies indicates conformational differences between the RNAse H domains of p 66 and p 15.

Authors:  A M Szilvay; S Nornes; A Kannapiran; B I Haukanes; C Endresen; D E Helland
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

3.  Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA in vitro.

Authors:  Y F Melekhovets; S Joshi
Journal:  Nucleic Acids Res       Date:  1996-05-15       Impact factor: 16.971

4.  HIV-1 Reverse Transcriptase Polymerase and RNase H (Ribonuclease H) Active Sites Work Simultaneously and Independently.

Authors:  An Li; Jiawen Li; Kenneth A Johnson
Journal:  J Biol Chem       Date:  2016-10-24       Impact factor: 5.157

5.  Transcription factor E2F binds DNA as a heterodimer.

Authors:  H E Huber; G Edwards; P J Goodhart; D R Patrick; P S Huang; M Ivey-Hoyle; S F Barnett; A Oliff; D C Heimbrook
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F.

Authors:  M Ivey-Hoyle; R Conroy; H E Huber; P J Goodhart; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

7.  E1 protein of human papillomavirus is a DNA helicase/ATPase.

Authors:  F J Hughes; M A Romanos
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

8.  Purification and characterization of an active human immunodeficiency virus type 1 RNase H domain.

Authors:  J S Smith; M J Roth
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit.

Authors:  Arianna Loregian; Roberto Rigatti; Mary Murphy; Elisabetta Schievano; Giorgio Palu; Howard S Marsden
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

10.  Yeast farnesyl-diphosphate synthase: site-directed mutagenesis of residues in highly conserved prenyltransferase domains I and II.

Authors:  L Song; C D Poulter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.